FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number: 3235-								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* ORBIMED ADVISORS LLC			2. Date of Eve Requiring Stat (Month/Day/Ye 03/22/2016	ement	3. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS]								
(Last) (First) (Middle) 601 LEXINGTON AVENUE (AT 53RD					4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					5. If Amendment, Date of Original Filed (Month/Day/Year)			
STREET), 54TH FLOOR						Officer (give title below)		Other (spe below)	, 1,	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street) NEW YORK	NY	10022-4629								Form		y More than One	
(City)	(State)	(Zip)											
Table I - Non-Derivative Securities Beneficially Owned													
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		ct (D) (In	4. Nature of Indirect Beneficial Ownership (Instr. 5)						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr.			4. Conversi or Exerci		•	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	Title			Amount or Number of Shares	Price of Derivative Security		irect		
Series A Conve	ertible Preferred	l Stock	(1)	(2)	(Common Stock		3,994,674	0.00		[See Footnotes ⁽³⁾⁽⁴⁾	
Series B Conve	ertible Preferred	l Stock	(1)	(2)	(Common Stock		713,776	0.00]		See Footnotes ⁽³⁾⁽⁴⁾	

Explanation of Responses:

- 1. The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock will automatically convert into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
- 2. The expiration date is not relevant to the conversion of these securities.
- 3. These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock are held of record by OrbiMed Private Investments V, LP ("OPI V"). OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to have beneficial ownership over such securities.
- 4. This report on Form 3 is jointly filed by GP V, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Peter A. Thompson ("Thompson"), an employee of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Thompson is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

<u>/s/ Samuel D. Isaly</u> <u>03/22/2016</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.